Jason D Iannuccilli1, Damian E Dupuy2, Michael D Beland2, Jason T Machan3, Dragan J Golijanin4, William W Mayo-Smith2. 1. Department of Radiology, Rhode Island Hospital, Alpert Medical School of Brown University, 593 Eddy St., Providence, RI, 02903, USA. jiannuccilli@lifespan.org. 2. Department of Radiology, Rhode Island Hospital, Alpert Medical School of Brown University, 593 Eddy St., Providence, RI, 02903, USA. 3. Department of Biostatistics, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI, 02903, USA. 4. Department of Urology, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI, 02903, USA.
Abstract
OBJECTIVES: To define effectiveness and safety of CT-guided radiofrequency ablation (RFA) of renal tumours and prognostic indicators for treatment success. METHODS: Patients with a single treatment of a solitary, biopsy-proven renal tumour with intent to cure over a 14-year period were included (n = 203). Probability of residual disease over time, complication rates and all-cause mortality were assessed in relation to multiple variables. RESULTS: Mean tumour size was 2.5 cm (range 1.0-6.0). Mean follow-up was 34.1 months (range 1-131). There was an increase in likelihood of residual disease for tumours ≥3.5 cm (P < 0.05), clear cell subtype of renal cell carcinoma (P ≤ 0.005) and maximum treatment temperature ≤70 °C (P < 0.05). There was a decrease in likelihood of residual disease for exophytic tumours (P = 0.01) and no difference based on age, gender, tumour location or type of radio freqency (RF) electrode used. Major complications occurred in 3.9 %. Median post-treatment survival was 7 years for patients with tumours <4 cm, and 5-year overall survival was 80 %. Probability of minor complication increased with tumour size (P = 0.03), as did all-cause mortality (P = 0.005). CONCLUSIONS: CT-guided RFA is safe and effective for early-stage renal cancer, particularly for exophytic tumours measuring <3.5 cm. Overall 5-year survival with tumours <4 cm is comparable to partial nephrectomy. KEY POINTS: • Prognostic indicators for success of CT-guided RFA of renal tumours are reported. • Tumour size ≥3.5 cm confers an increased risk for residual tumour. • Clear cell renal cell carcinoma subtype confers increased risk for residual tumour. • Tmax <70 °C within the ablation zone confers increased risk for residual tumour. • Exophytic tumours have a lower probability of residual disease.
OBJECTIVES: To define effectiveness and safety of CT-guided radiofrequency ablation (RFA) of renal tumours and prognostic indicators for treatment success. METHODS:Patients with a single treatment of a solitary, biopsy-proven renal tumour with intent to cure over a 14-year period were included (n = 203). Probability of residual disease over time, complication rates and all-cause mortality were assessed in relation to multiple variables. RESULTS: Mean tumour size was 2.5 cm (range 1.0-6.0). Mean follow-up was 34.1 months (range 1-131). There was an increase in likelihood of residual disease for tumours ≥3.5 cm (P < 0.05), clear cell subtype of renal cell carcinoma (P ≤ 0.005) and maximum treatment temperature ≤70 °C (P < 0.05). There was a decrease in likelihood of residual disease for exophytic tumours (P = 0.01) and no difference based on age, gender, tumour location or type of radio freqency (RF) electrode used. Major complications occurred in 3.9 %. Median post-treatment survival was 7 years for patients with tumours <4 cm, and 5-year overall survival was 80 %. Probability of minor complication increased with tumour size (P = 0.03), as did all-cause mortality (P = 0.005). CONCLUSIONS: CT-guided RFA is safe and effective for early-stage renal cancer, particularly for exophytic tumours measuring <3.5 cm. Overall 5-year survival with tumours <4 cm is comparable to partial nephrectomy. KEY POINTS: • Prognostic indicators for success of CT-guided RFA of renal tumours are reported. • Tumour size ≥3.5 cm confers an increased risk for residual tumour. • Clear cell renal cell carcinoma subtype confers increased risk for residual tumour. • Tmax <70 °C within the ablation zone confers increased risk for residual tumour. • Exophytic tumours have a lower probability of residual disease.
Authors: S Nahum Goldberg; Clement J Grassi; John F Cardella; J William Charboneau; Gerald D Dodd; Damian E Dupuy; Debra Gervais; Alice R Gillams; Robert A Kane; Fred T Lee; Tito Livraghi; John McGahan; David A Phillips; Hyunchul Rhim; Stuart G Silverman Journal: Radiology Date: 2005-04-21 Impact factor: 11.105
Authors: Ioannis M Varkarakis; Mohamad E Allaf; Takeshi Inagaki; Sam B Bhayani; David Y Chan; Li-Ming Su; Thomas W Jarrett; Louis R Kavoussi; Stephen B Solomon Journal: J Urol Date: 2005-08 Impact factor: 7.450
Authors: Michael D Beland; Farrah J Wolf; David J Grand; Damian E Dupuy; William W Mayo-Smith Journal: AJR Am J Roentgenol Date: 2011-09 Impact factor: 3.959
Authors: Matthew S Davenport; Elaine M Caoili; Richard H Cohan; James H Ellis; Ellen J Higgins; Jonathon Willatt; Giovanna A Fox Journal: AJR Am J Roentgenol Date: 2009-06 Impact factor: 3.959
Authors: David J Breen; Elizabeth E Rutherford; Brian Stedman; Shuvro H Roy-Choudhury; James E I Cast; Matthew C Hayes; Christopher J Smart Journal: Cardiovasc Intervent Radiol Date: 2007-06-18 Impact factor: 2.740
Authors: Brigit M Aarts; Fernando M Gomez; Marta Lopez-Yurda; Rob F M Bevers; Joris Herndriks; Regina G H Beets-Tan; Axel Bex; Elisabeth G Klompenhouwer; Rutger W van der Meer Journal: Eur Radiol Date: 2022-09-06 Impact factor: 7.034